Topics:

'More May Be Less' in Metastatic Cervical Cancer

'More May Be Less' in Metastatic Cervical Cancer

VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group (GCCG) has challenged the assumption that aggressive combination chemotherapy is worthwhile in chemotherapy-naïve women with metastatic squamous cell cancer of the cervix.

Although a highly active four-drug combination yielded a response rate superior to that seen with cisplatin alone, it resulted in substantially greater hematologic and nonhematologic toxicity, and afforded no survival advantage, Dr. Jan Vermorken of Amsterdam's Free University Hospital, said at the European Society for Medical Oncology Congress.

The study documented a 31% response rate in the 143 women assigned to BEMP (bleomycin, vindesine, mitomycin C, cisplatin) versus 19% in the 144 platinum-treated patients.

This benefit was achieved at the cost of more frequent complications, treatment delays, and dose reductions. At 6 years' follow-up, survival curves for the two regimens were superimposable.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.